Precede Biosciences

Weve experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, weve developed a simple blood test to uncover actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, were working towards a world where new medicine development efforts succeed more frequently, and where anyone...

Biotechnology,oncology,plasma,precision medicine,genomic liquid biopsy,drug development,biology,human biology,human biology,cancer,molecular biology,machine learning,ai,artificial intelligence,genomic medicine,and target medicines

Precede biosciences operates in the Biotechnology research industry.

Precede biosciences's revenue is 1m - 10m

Precede biosciences has 11 - 50 employees.